National Law's Tweets National Law on Facebook

HEART SURGERY PATIENTS: TRASYLOL® CAUSES KIDNEY FAILURE


If you received Trasylol® during heart surgery please complete our short CONFIDENTIAL contact form on the right side of this page or call us immediately at TOLL FREE 1.800.467.4000. We will thoroughly examine your case, answer your questions, and inform you of your legal rights and options.

The heart drug Trasylol®—which is sometimes used to control bleeding during heart surgery—has recently been the subject of various independent studies. When the safety of Trasylol® was tested in January 2006, the results were shocking. Patients who were given Trasylol® suffered double the risk of stroke, heart failure, heart attack, and kidney failure.

It is estimated that Trasylol® is responsible for 11,050 kidney complications, and 1 billion dollars in healthcare costs.

If you had heart surgery, including heart bypass surgery, you may have been given the drug Trasylol during surgery. Check with your surgeon immediately!

If you received Trasylol® please complete our short CONFIDENTIAL contact form on the right side of this page or call us immediately at TOLL FREE 1.800.467.4000. We will thoroughly examine your case, answer your questions, and inform you of your legal rights and options.


Serious Risks of Trasylol®

In a study of 4,300 heart surgery patients who were treated with Trasylol®, a generic alternative, or nothing at all, researchers found that patients who were given Trasylol® faced more than double the risk of serious side effects. Specifically, patients treated with Trasylol® experienced life-threatening side effects at a rate of 2.8 percent compared with only 1.3 percent of other patients.

The dangerous side effects of Trasylol® include:

50% increased risk of heart attack
Double the risk of renal failure
181% increase in the risk of stroke

Trasylol® and Your Rights

The recent testing of Trasylol® has caused great concern in the medical field, and even stopped its use by some specialists. It is believed that the life threatening effects of Trasylol have been seriously underestimated due to inadequate risk testing by pharmaceutical companies. If you have been treated with Trasylol® and suffered its effects, you are not alone.


FDA Issues Safety Alert on Trasylol®

Manufacturer Removes Remaining Stocks of Trasylol

Background: On Nov. 5, 2007, the U.S. Food and Drug Administration announced that Bayer Pharmaceuticals Corp. agreed to an FDA-requested marketing suspension of Trasylol, a drug used to control bleeding during heart surgery. At that time, preliminary results from a Canadian study suggested an increased risk for death compared to two other drugs used to control bleeding.

Bayer HealthCare Pharmaceuticals Inc. has notified the FDA that the company will begin removing the remaining Trasylol stock from the U.S. market, most of which is in warehouses and hospital or physician’s stock. The FDA will work with Bayer to ensure a smooth and complete process.

Under a limited use agreement, access to Trasylol is limited to investigational use of the drug according to the procedures described in a special treatment protocol. The protocol allows treatment for certain patients who are at increased risk of blood loss and transfusions during coronary artery bypass graft surgery and who have no acceptable alternative therapy. Physicians using Trasylol in this situation must also verify that the benefits of the drug clearly outweigh the risks for their patients.

FDA limits access to certain drugs to patients with serious or immediately life-threatening disease or conditions who lack other therapeutic options and may benefit from such therapies. This type of access requires the submission of a protocol, which is reviewed and approved by the agency. Bayer has agreed to provide Trasylol through this mechanism for the limited use described above.

Trasylol is an antifibrinolytic drug approved to reduce blood loss during surgery and the need for blood transfusion in certain patient undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery. Antifibrinolytic drugs help slow the breakdown of blood clots and subsequent excessive bleeding.

Results from a randomized Canadian study that prompted last November’s marketing suspension of Trasylol are expected to be published this week. The data contained in this article suggest that Trasylol appears to increase the risk for death compared to two other antifibrinolytic drugs used in the study.

The findings from this randomized study are similar to those from an observational study that was discussed at a September 2007 FDA advisory committee meeting. Based upon the data available at the time, the advisory committee recommended continued marketing of Trasylol. However, FDA requested the marketing suspension in the interest of patient safety based on the serious nature of the outcomes suggested in the preliminary data. The committee also advised that a large, randomized clinical study was needed to further assess Trasylol’s safety compared to other drugs. This recently published Canadian study helps address this need for additional information.

The FDA has not yet received full study data from the study’s researchers at the Ottawa Health Research Institute but supports Bayer’s decision to completely remove Trasylol from regular use in the U.S. market. FDA is also reviewing the available Canadian study data to reassess the currently active special treatment protocol that provides access to Trasylol.

FDA oversight requires comprehensive and thorough studies of a drug not only during the pre-market review phase but throughout the drug’s life cycle. As studies and data on Trasylol emerged over the years, FDA actions included labeling changes, safety communications to physicians and other health care professionals, public discussion and review of study data at two Advisory Committee meetings, as well as close scrutiny of the ongoing studies.

The agency will consider a variety of study designs to support the review process for future antifibrinolytics, and will incorporate into these considerations information from the recently published Canadian study. FDA will continue to publicly disseminate safety information.

If you received Trasylol® during heart surgery please complete our short CONFIDENTIAL contact form on the right side of this page or call us immediately at TOLL FREE
1.800.467.4000. We will thoroughly examine your case, answer your questions, and inform you of your legal rights and options.

CONTACT US 1.800.467.4000
Home Phone

I agree to the Terms and Conditions.

Type these numbers into the box:
Captcha

HERE'S HOW WE WORK

Once you complete the Form above we will review your facts and contact you. Rest assured your information remains CONFIDENTIAL & PRIVATE. We understand the sensitive nature of your situation and will protect your privacy as we answer your questions and investigate your case.

We will gather further information from you as we determine whether filing a lawsuit on your behalf would be appropriate. We won't begin working on your case until you hire us by signing our Retainer Agreement which outlines all the details of our relationship. We will discuss all your options with you and answer any questions you may have.

We know this may all seem a bit confusing and perhaps a little overwhelming - don't worry! We will be with you every step of the way, handling all the paperwork and details. So fill out the Form above and let us help you get the answers and compensation you deserve.
Houston